Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Leukemia|July 5, 2022
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosisAndreas Reiter, Jason Gotlib, Iván Álvarez-Twose, et al.
Cancer|April 13, 2016
The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study GroupHolly L Geyer, Bjorn Andreasson, Heidi E Kosiorek, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|June 27, 2025
Patient-Reported Outcomes and Provider Perceptions of Systemic Mastocytosis: Results From the PRISM StudyMassimo Triggiani, Jessica Hobart, Iván Alvarez-Twose, et al.
Nature Medicine|December 7, 2021
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trialJason Gotlib, Andreas Reiter, Deepti H Radia, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 28, 2022
Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical PracticePeter Valent, Karin Hartmann, Juliana Schwaab, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 31, 2024
Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNMPeter Valent, Karin Hartmann, Gregor Hoermann, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 20, 2022
Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic MastocytosisJason Gotlib, Juliana Schwaab, William Shomali, et al.
Journal of the American Academy of Dermatology|February 14, 2026
Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER studyFrank Siebenhaar, Sigurd Broesby-Olsen, Mariana Castells, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 12, 2023
The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαTPeter Valent, Gregor Hoermann, Patrizia Bonadonna, et al.
The Journal of Allergy and Clinical Immunology|April 15, 2026
Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 yearsCem Akin, Vito Sabato, Jason Gotlib, et al.
Pageof 4